

MAYLEBEN TIMOTHY M

Form 4

June 11, 2018

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
MAYLEBEN TIMOTHY M

(Last) (First) (Middle)

C/O LOXO ONCOLOGY, INC., 281
TRESSER BLVD, 9TH FLOOR

(Street)

STAMFORD, CT 06901

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading
Symbol

Loxo Oncology, Inc. [LOXO]

3. Date of Earliest Transaction
(Month/Day/Year)

06/08/2018

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

☒ Director ☐ 10% Owner
☐ Officer (give title below) ☐ Other (specify below)

6. Individual or Joint/Group Filing(Check
Applicable Line)

☒ Form filed by One Reporting Person
☐ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/08/2018		M	7,416 A \$ 20.91	7,416	D	
Common Stock	06/08/2018		M	2,584 A \$ 24.18	10,000	D	
Common Stock	06/08/2018		S	10,000 (1) D \$ (2) 179.5469 0	0	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of
information contained in this form are not
required to respond unless the form**

SEC 1474
(9-02)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. F Sec (In	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	\$ 20.91	06/08/2018		M		7,416		<u>(3)</u>	07/27/2025	Common Stock	7,416
Director Stock Option (right to buy)	\$ 24.18	06/08/2018		M		2,584		<u>(4)</u>	06/09/2026	Common Stock	2,584

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other

MAYLEBEN TIMOTHY M
C/O LOXO ONCOLOGY, INC.
281 TRESSER BLVD, 9TH FLOOR
STAMFORD, CT 06901

/s/ Jennifer Burstein, by power of attorney
06/11/2018

**Signature of Reporting Person
Date

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Represents the aggregate of sales effected on the same day at different prices.

Edgar Filing: MAYLEBEN TIMOTHY M - Form 4

- Represents the weighted average sales price per share. The shares sold at prices ranging from \$179.00 to \$180.37 per share. Full
- (2) information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
 - (3) The stock option vests and becomes exercisable as to 1/3 of the shares subject to the option on the one-year anniversary of the grant date, and thereafter vests as to an additional 1/3 of the shares annually.
 - (4) The stock option is fully vested and immediately exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.